I do not have a position in NKTR, but from what I have read it looks like a high quality company. I'm not sure what to make of the new CEO. I like the fact that multiple drugs using its technology are in clinical trials (diversifying regulatory risk). Couple of questions.
Is NKTR's revenue stream sufficient for its 1+ Billion dollar market cap?
Does NKTR need more than royalty revenue in order to grow into a large-cap biotech?
Should/Are biotechs that rely on licensing technology valued differently that product-based biotech companies?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.